Expression pattern of matrix metalloproteinases-2 and -9 and their tissue inhibitors in patients with chronic inflammatory demyelinating polyneuropathy
Related Experiment Video
Updated: Nov 5, 2025
Detection of Functional Matrix Metalloproteinases by Zymography
Published on: November 8, 2010
Giuseppe Cosentino1,2, Vincenzo Di Stefano3, Rosalia Lo Presti4
1Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. giuseppe.cosentino@unipv.it.
Background:
Matrix metalloproteinases (MMPs) are a heterogeneous family of endopeptidases that play a role in many physiological functions, including the immune response. An imbalance between the activity of MMPs and their physiological tissue inhibitors (TIMPs) has been proposed in the pathophysiology of different autoimmune disorders. We aimed to assess the plasmatic levels of MMP-2, MMP-9, and their inhibitors TIMP-1 and -2 in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Subjects And Methods:
Twenty patients with CIDP and 20 age- and sex-matched healthy controls were enrolled. Plasma concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined by the enzyme-linked immunosorbent assay.
Results:
CIDP subjects had higher MMP-9 concentrations along with TIMP-1 downregulation when compared to controls, with the consequent increase in the MMP-9/TIMP-1 ratio (p<0.000002 for all measures). Conversely, the concentration of MMP-2 was lower in the CIDP group (p<0.01) without changes in the TIMP-2 concentration. The MMP-2/TIMP-2 ratio was decreased in the patients' group (p<0.02).
Discussion:
We provide first preliminary evidence that the plasmatic pattern of MMPs and TIMPs is markedly altered in patients with CIDP. Future studies are needed to assess the potential usefulness of these new biomarkers in the clinical setting.
Insights
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) show altered levels in chronic inflammatory demyelinating polyneuropathy (CIDP). This study found increased MMP-9/TIMP-1 ratios and decreased MMP-2/TIMP-2 ratios in CIDP patients.
Area of Science:
- Neuroimmunology
- Biochemistry
- Molecular Biology
Background:
- Matrix metalloproteinases (MMPs) are crucial for immune responses.
- Imbalances in MMPs and their inhibitors (TIMPs) are implicated in autoimmune diseases.
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder.
Purpose of the Study:
- To investigate plasmatic levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 in CIDP patients.
- To determine if MMP/TIMP profiles differ between CIDP patients and healthy controls.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify MMP-2, MMP-9, TIMP-1, and TIMP-2.
- Plasma samples from 20 CIDP patients and 20 healthy controls were analyzed.
Main Results:
- CIDP patients exhibited significantly higher MMP-9 concentrations and lower TIMP-1 levels, increasing the MMP-9/TIMP-1 ratio.
- MMP-2 concentrations were lower in CIDP patients, while TIMP-2 levels remained unchanged, decreasing the MMP-2/TIMP-2 ratio.
Conclusions:
- Preliminary evidence suggests a distinct plasmatic MMP and TIMP profile in CIDP.
- These MMPs and TIMPs may serve as potential biomarkers for CIDP in clinical settings.
